3-(3,5-Difluorophenyl)-5,5-dimethyl-2-hydroxy-4-(4-(methylsulfonyl)phenyl)-2,5-dihydrofuran | 190966-04-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-(3,5-Difluorophenyl)-5,5-dimethyl-2-hydroxy-4-(4-(methylsulfonyl)phenyl)-2,5-dihydrofuran
• 英文别名: 3-(3,5-difluorophenyl)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-2H-furan-2-ol
• CAS: 190966-04-2
• 化学式: C₁₉H₁₈F₂O₄S
• 分子量: 380.412
• InChiKey: TYCIQSPLNIGWBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2016021742A1

  公开（公告）日：2016-02-11

  The present invention provides a compound represented by the formula (1) : wherein each symbol is as defined in the specification or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm, endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

  本发明提供了一种化合物，其化学式表示为（1）：其中每个符号如规范中定义或其盐具有EP4受体拮抗作用，并且可用作预防或治疗与EP4受体相关疾病（例如类风湿性关节炎、主动脉瘤、子宫内膜异位症、强直性脊柱炎、炎性乳腺癌等）等的药剂。
• [EN] 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS<br/>[FR] 3,4-DIARYLE-2-HYDROXY-2,5-DIHYDROFURANS UTILISES COMME PROMEDICAMENTS POUR INHIBITEURS DE COX-2
  申请人：MERCK FROSST CANADA INC.

  公开号：WO1997016435A1

  公开（公告）日：1997-05-09

  (EN) The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).(FR) L'invention se rapporte à un nouveau composé de la formule (I) utile dans le traitement de pathologies induites par la cyclooxygénase-2. L'invention se rapporte également à certaines compositions pharmaceutiques destinées au traitement de pathologies induites par la cyclooxygénase-2 et comprenant les composés de la formule (I).

  该发明涵盖了式（I）的新型化合物，可用于治疗环氧合酶-2介导的疾病。该发明还涵盖了某些含有式（I）化合物的药物组合物，用于治疗环氧合酶-2介导的疾病。
• Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
  申请人：Sen Nilendu

  公开号：US20050100594A1

  公开（公告）日：2005-05-12

  Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms.

  本发明公开了一种缓释药物制剂，该制剂由肌肉松弛剂药物（如替扎尼丁）与环氧化酶-2 抑制剂（如伐地昔布）组合而成。该制剂可用于治疗和控制与骨骼肌痉挛等相关的疼痛性炎症。
• Topical pharmaceutical compositions
  申请人：Krishnan Anandi

  公开号：US20050096371A1

  公开（公告）日：2005-05-05

  A hydroalcoholic topical pharmaceutical composition is provided comprising a therapeutically effective amount of a therapeutic agent comprising one or more selective cyclooxygenase-2 (COX-2) inhibitors or pharmaceutically acceptable salts or esters thereof solubilized in a solubilizing amount of a penetration vehicle system comprising a skin penetration enhancing effective amount of at least one monohydric alcohol and at least two non-volatile organic compounds selected from the group consisting of pyrrolidones, polyol ethers, polyols and mixtures thereof. Also provided is a process for its preparation.

  本发明提供了一种水醇局部药物组合物，该组合物包含治疗有效量的治疗剂，该治疗剂包含一种或多种选择性环氧化酶-2 (COX-2) 抑制剂或其药学上可接受的盐或酯，该治疗剂溶解在渗透载体系统的溶解量中，该渗透载体系统包含皮肤渗透增强有效量的至少一种一元醇和至少两种非挥发性有机化合物，这些非挥发性有机化合物选自由吡咯烷酮、多元醇醚、多元醇及其混合物组成的组。此外，还提供了一种制备方法。
• Sulfonanilide compounds
  申请人：TAISHO PHARMACEUTICAL CO. LTD

  公开号：EP0317332B1

  公开（公告）日：1993-05-19